Pharmaceutical Industry Practices on Genotoxic Impurities (eBook, ePUB)
Redaktion: Lee, Heewon
180,95 €
180,95 €
inkl. MwSt.
Sofort per Download lieferbar
90 °P sammeln
180,95 €
Als Download kaufen
180,95 €
inkl. MwSt.
Sofort per Download lieferbar
90 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
180,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
90 °P sammeln
Pharmaceutical Industry Practices on Genotoxic Impurities (eBook, ePUB)
Redaktion: Lee, Heewon
- Format: ePub
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung

Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.

Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
A great deal of confusion and uncertainty over genotoxic impurity (GTI) identification, assessment, and control exists in the pharmaceutical industry today. Pharmaceutical Industry Practices on Genotoxic Impurities strives to facilitate scientific and systematic consensus on GTI management by presenting rationales, strategies, methods, interpretati
- Geräte: eReader
- mit Kopierschutz
- eBook Hilfe
Andere Kunden interessierten sich auch für
- Pharmaceutical Industry Practices on Genotoxic Impurities (eBook, PDF)180,95 €
- Good Clinical Practices in Pharmaceuticals (eBook, ePUB)53,95 €
- Robert ThomasMeasuring Elemental Impurities in Pharmaceuticals (eBook, ePUB)48,95 €
- Harry G. BrittainSpectroscopy of Pharmaceutical Solids (eBook, ePUB)64,95 €
- Richard SchulzPatient Compliance with Medications (eBook, ePUB)30,95 €
- Transdermal Drug Delivery Systems (eBook, ePUB)63,95 €
- Calibration in the Pharmaceutical Laboratory (eBook, ePUB)53,95 €
-
-
-
A great deal of confusion and uncertainty over genotoxic impurity (GTI) identification, assessment, and control exists in the pharmaceutical industry today. Pharmaceutical Industry Practices on Genotoxic Impurities strives to facilitate scientific and systematic consensus on GTI management by presenting rationales, strategies, methods, interpretati
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis eBooks
- Erscheinungstermin: 29. August 2014
- Englisch
- ISBN-13: 9781040162392
- Artikelnr.: 72520099
- Verlag: Taylor & Francis eBooks
- Erscheinungstermin: 29. August 2014
- Englisch
- ISBN-13: 9781040162392
- Artikelnr.: 72520099
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
Heewon Lee is Senior Associate Director of the Chemical Development Department at Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA. She is also leader of the Analytical Research Group, an active participant in the Genotoxic Impurity Council, and a member of the Pharmaceutical IQ Consortium Working Group. She holds a BS and a MS from Seoul National University, South Korea, as well as a Ph.D from the University of Michigan, Ann Arbor, USA. Previously, she worked at ArQule, a biotechnology company located in Woburn, Massachusetts, USA. After ArQule, she joined the Medicinal Chemistry Department at Boehringer-Ingelheim before moving to her current position.
Overview of Regulatory Guidelines on Impurities and Genotoxic Impurities.
Structural Alerts for Genotoxicity and Carcinogenicity. Acceptable Exposure
Calculations for Impurities and Selected Compounds from the Carcinogenic
Potency Database. Genotoxic Impurities from Toxicology Perspectives
Including Cancer Risk Assessment, In Silico, In Vitro/In Vivo Testings, and
Regulatory Aspects. In Silico/Computational Assessment for the Evaluation
of Genotoxic Impurities. Preclinical Assessment of Genotoxic Impurities: An
Overview of Current Regulatory Guidance, Available Assays, and Data
Interpretation. Purification of Lead Compounds for Early Toxicology
Profiling such as Ames and Short-Term Nongood Laboratory Practice
Toxicology Tests. Analysis of Genotoxic Impurities in Pharmaceuticals by
Gas Chromatography-Mass Spectrometry. Control of Chloroethane in Raw
Materials and Drug Substances Using Headspace/Gas Chromatography Analysis.
Quantification of Genotoxic Impurities in Active Pharmaceutical
Ingredients. Analytical Testing and Control for Genotoxic Impurities in
Drug Substances. Approaches to Assess, Analyze, and Control Genotoxic
Impurities in Drug Substance Development. Control and Analysis of Genotoxic
Impurities in Drug Substance Development. Salt Formation of Pharmaceutical
Compounds and Associated Genotoxic Risks. Identification and Control of
Genotoxic Degradation Products. Identification and Qualification of
Genotoxic Impurities as Leachables in Drug Products. Pharmaceutical
Industry Survey on Genotoxic Impurities and Related Topics.
Structural Alerts for Genotoxicity and Carcinogenicity. Acceptable Exposure
Calculations for Impurities and Selected Compounds from the Carcinogenic
Potency Database. Genotoxic Impurities from Toxicology Perspectives
Including Cancer Risk Assessment, In Silico, In Vitro/In Vivo Testings, and
Regulatory Aspects. In Silico/Computational Assessment for the Evaluation
of Genotoxic Impurities. Preclinical Assessment of Genotoxic Impurities: An
Overview of Current Regulatory Guidance, Available Assays, and Data
Interpretation. Purification of Lead Compounds for Early Toxicology
Profiling such as Ames and Short-Term Nongood Laboratory Practice
Toxicology Tests. Analysis of Genotoxic Impurities in Pharmaceuticals by
Gas Chromatography-Mass Spectrometry. Control of Chloroethane in Raw
Materials and Drug Substances Using Headspace/Gas Chromatography Analysis.
Quantification of Genotoxic Impurities in Active Pharmaceutical
Ingredients. Analytical Testing and Control for Genotoxic Impurities in
Drug Substances. Approaches to Assess, Analyze, and Control Genotoxic
Impurities in Drug Substance Development. Control and Analysis of Genotoxic
Impurities in Drug Substance Development. Salt Formation of Pharmaceutical
Compounds and Associated Genotoxic Risks. Identification and Control of
Genotoxic Degradation Products. Identification and Qualification of
Genotoxic Impurities as Leachables in Drug Products. Pharmaceutical
Industry Survey on Genotoxic Impurities and Related Topics.
Overview of Regulatory Guidelines on Impurities and Genotoxic Impurities.
Structural Alerts for Genotoxicity and Carcinogenicity. Acceptable Exposure
Calculations for Impurities and Selected Compounds from the Carcinogenic
Potency Database. Genotoxic Impurities from Toxicology Perspectives
Including Cancer Risk Assessment, In Silico, In Vitro/In Vivo Testings, and
Regulatory Aspects. In Silico/Computational Assessment for the Evaluation
of Genotoxic Impurities. Preclinical Assessment of Genotoxic Impurities: An
Overview of Current Regulatory Guidance, Available Assays, and Data
Interpretation. Purification of Lead Compounds for Early Toxicology
Profiling such as Ames and Short-Term Nongood Laboratory Practice
Toxicology Tests. Analysis of Genotoxic Impurities in Pharmaceuticals by
Gas Chromatography-Mass Spectrometry. Control of Chloroethane in Raw
Materials and Drug Substances Using Headspace/Gas Chromatography Analysis.
Quantification of Genotoxic Impurities in Active Pharmaceutical
Ingredients. Analytical Testing and Control for Genotoxic Impurities in
Drug Substances. Approaches to Assess, Analyze, and Control Genotoxic
Impurities in Drug Substance Development. Control and Analysis of Genotoxic
Impurities in Drug Substance Development. Salt Formation of Pharmaceutical
Compounds and Associated Genotoxic Risks. Identification and Control of
Genotoxic Degradation Products. Identification and Qualification of
Genotoxic Impurities as Leachables in Drug Products. Pharmaceutical
Industry Survey on Genotoxic Impurities and Related Topics.
Structural Alerts for Genotoxicity and Carcinogenicity. Acceptable Exposure
Calculations for Impurities and Selected Compounds from the Carcinogenic
Potency Database. Genotoxic Impurities from Toxicology Perspectives
Including Cancer Risk Assessment, In Silico, In Vitro/In Vivo Testings, and
Regulatory Aspects. In Silico/Computational Assessment for the Evaluation
of Genotoxic Impurities. Preclinical Assessment of Genotoxic Impurities: An
Overview of Current Regulatory Guidance, Available Assays, and Data
Interpretation. Purification of Lead Compounds for Early Toxicology
Profiling such as Ames and Short-Term Nongood Laboratory Practice
Toxicology Tests. Analysis of Genotoxic Impurities in Pharmaceuticals by
Gas Chromatography-Mass Spectrometry. Control of Chloroethane in Raw
Materials and Drug Substances Using Headspace/Gas Chromatography Analysis.
Quantification of Genotoxic Impurities in Active Pharmaceutical
Ingredients. Analytical Testing and Control for Genotoxic Impurities in
Drug Substances. Approaches to Assess, Analyze, and Control Genotoxic
Impurities in Drug Substance Development. Control and Analysis of Genotoxic
Impurities in Drug Substance Development. Salt Formation of Pharmaceutical
Compounds and Associated Genotoxic Risks. Identification and Control of
Genotoxic Degradation Products. Identification and Qualification of
Genotoxic Impurities as Leachables in Drug Products. Pharmaceutical
Industry Survey on Genotoxic Impurities and Related Topics.